Genetically engineered red cells expressing single domain camelid antibodies confer long-term protection against botulinum neurotoxin
The therapeutic use of single-chain antibodies (VHHs) is limited by their short half-life in the circulation. Here the authors engineer mouse and human red blood cells to express VHHs against botulinum neurotoxin A (BoNT/A) on their surface and show that an infusion of these cells into mice confers...
Guardado en:
Autores principales: | Nai-Jia Huang, Novalia Pishesha, Jean Mukherjee, Sicai Zhang, Rhogerry Deshycka, Valentino Sudaryo, Min Dong, Charles B. Shoemaker, Harvey F. Lodish |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/cc5b7658df0d48e1aa16746d22081aea |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
A camelid single-domain antibody neutralizes botulinum neurotoxin A by blocking host receptor binding
por: Guorui Yao, et al.
Publicado: (2017) -
Engineered red blood cells carrying PCSK9 inhibitors persistently lower LDL and prevent obesity.
por: Rhogerry Deshycka, et al.
Publicado: (2021) -
Engineered red blood cells carrying PCSK9 inhibitors persistently lower LDL and prevent obesity
por: Rhogerry Deshycka, et al.
Publicado: (2021) -
Identification and characterization of a novel botulinum neurotoxin
por: Sicai Zhang, et al.
Publicado: (2017) -
On Botulinum Neurotoxin Variability
por: Cesare Montecucco, et al.
Publicado: (2015)